Description: Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The company is involved in developing oral anticoagulants for various cardiovascular indications with novel pharmacology; kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema; and novel angiogenesis inhibitors for the treatment of solid tumors, as well as metabolic disorders. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.
Exchange: NYSE ARCA
Country: US : United States of America
Currency: US Dollar ($)
Category: Technology
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 87.64 | 0.00 | 87.64 |
| Stock non-US | 12.28 | 0.00 | 12.28 |
| Other | 0.08 | 0.00 | 0.08 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Technology | 62.93 | 76.83 |
| Communication Services | 26.20 | 8.04 |
| Consumer Cyclicals | 5.26 | 5.36 |
| Real Estate | 3.36 | 0.35 |
| Healthcare | 2.25 | 1.37 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 87.71 | 90.79 |
| Asia Emerging | 6.76 | 1.10 |
| Asia Developed | 4.11 | 2.58 |
| Japan | 1.42 | 0.70 |
| Australasia | 0.00 | 0.06 |
| Latin America | 0.00 | 0.27 |
| United Kingdom | 0.00 | 0.33 |
| Europe Developed | 0.00 | 3.57 |
| Africa/Middle East | 0.00 | 0.61 |